European Committee for Treatment & Research in Multiple Sclerosis

Startseite
Schweiz
Basel
European Committee for Treatment & Research in Multiple Sclerosis

The European Committee for Treatment & Research in Multiple Sclerosis - the world's largest organisat

SAVE THE DATE: MSMilan2023, the 9th joint ECTRIMS-ACTRIMS meeting, will be held as a hybrid event on 11–13 October in Milan, Italy

19/02/2026

ECTRIMS and the National Multiple Sclerosis Society are pleased to announce the appointment of four distinguished experts to the International Advisory Committee on Clinical Trials in Multiple Sclerosis (IACCTMS). The Committee provides perspective and guidance on planning and implementing clinical trials for the treatment of .

Joining the Committee as of 1 January 2026:

- Ethel Ciampi, MD, Pontificia Universidad Católica de Chile (Chile)
- Kate Fitzgerald, PhD, The Johns Hopkins University (United States)
- Pascal Sati, PhD, Cedars-Sinai Health System (United States)
- Heinz Wiendl, MD, Universitätsklinikum Freiburg (Germany)

These appointments underscore the Committee’s momentum in advancing innovative, patient-centred clinical research, reinforcing its role in shaping the future of MS trials through cross-disciplinary and international expertise.

The Committee extends its sincere appreciation to the following members who have completed their terms:

- Frederik Barkhof, MD, PhD, UCL (United Kingdom)
- Jorge Correale, MD, Raúl Carrea Institute for Neurological Research (Argentina)
- Marcia Finlayson, PhD, Queen's University (Canada)
- Amber Salter, PhD, University of Texas Southwestern Medical Center (United States)

Read the full press release: https://ectrims.eu/press/international-advisory-committee-on-clinical-trials-in-ms-welcomes-new-members/

18/02/2026

From Winter School collaboration to peer-reviewed publication 🎉

A project initiated at the 2024 ECTRIMS Winter School in Innsbruck has now been published in the Multiple Sclerosis Journal.

👉Read it here: https://bit.ly/4akZuXR

First-authored by Roxanne Pretzsch, Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and Universitätsspital Basel (USB), this meta-regression of randomised controlled trials (RCTs) shows that neurofilament light chain (NfL) is a promising biomarker for monitoring treatment response in people with multiple sclerosis (MS).

Across 15 RCTs – 9 in relapsing MS and 6 in progressive MS – treatment effects on serum/plasma NfL demonstrated moderate associations with MRI lesion activity, annualised relapse rate and disability worsening.

This publication reflects the value of the ECTRIMS Winter School as both an educational initiative and a platform that fosters collaboration and research among early-career investigators.

17/02/2026

🦠What role does Epstein–Barr virus play in the development of multiple sclerosis?

👉 Read our latest Spotlight here: https://bit.ly/4rBMKlh

This article explores how EBV infection may contribute to MS pathogenesis — and why the timing of infection matters.

“Epidemiological data suggest that EBV is a 𝘤𝘰𝘯𝘥𝘪𝘤𝘪𝘰 𝘴𝘪𝘯𝘦 𝘲𝘶𝘢 𝘯𝘰𝘯 for the development of MS, but it is not sufficient on its own. So, what are the other factors?” says Professor Christian Münz of the Universität Zürich.

“In the end, it would be necessary to have a vaccination strategy against EBV”, adds Professor Tobias Derfuss of the Universität Basel. “Demonstrating that such strategies can reduce MS risk would provide the strongest evidence for a causal link between EBV and MS.”

✍️ The ECTRIMS Spotlight Series is curated and authored by our Scientific Content Writer, Stefania De Vito, PhD.

16/02/2026

| Beyond the Congress

We hope you have enjoyed exploring the Best of Slide Decks and found it valuable in your daily practice. This easy-to-access resource showcases the very best of the science presented in Barcelona.

📥 Keep strengthening the MS community—download and share the slides with your colleagues and peers via myECTRIMS ➡️ https://my.ectrims.eu/bestofslidedecks

12/02/2026

🎧 𝐂𝐚𝐧 𝐧𝐞𝐰 𝐭𝐫𝐢𝐚𝐥 𝐝𝐚𝐭𝐚 𝐜𝐡𝐚𝐧𝐠𝐞 𝐭𝐡𝐞 𝐨𝐮𝐭𝐥𝐨𝐨𝐤 𝐟𝐨𝐫 𝐩𝐫𝐨𝐠𝐫𝐞𝐬𝐬𝐢𝐯𝐞 𝐌𝐒?

New data presented last week at ACTRIMS Forum 2026 on fenebrutinib suggest BTK inhibition may help bridge that gap – targeting peripheral immune activity and compartmentalised CNS processes driving progression.

In our latest podcast episode, FENtrepid trial leads, Prof. Amit Bar-Or from University of Pennsylvania and Dr. Stephen Hauser from UCSF, speak with host Brett Drummond of MStranslate about why BTK inhibition uniquely targets the cells most implicated in chronic MS progression.

𝐋𝐢𝐬𝐭𝐞𝐧 𝐧𝐨𝐰:

• Spotify: https://bit.ly/4qq9bcb
• Apple: https://apple.co/4bKafEh
• Website: https://bit.ly/4tjq1MN

Unity Health Toronto, Queen Mary University of London, Università di Genova, Universitätsmedizin Göttingen - UMG, Fraunhofer ITEM, Universität Basel, OhioHealth, Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB)

11/02/2026

𝐖𝐡𝐞𝐫𝐞 𝐝𝐨 𝐭𝐡𝐞 𝐰𝐨𝐫𝐥𝐝’𝐬 𝐥𝐞𝐚𝐝𝐢𝐧𝐠 𝐌𝐒 𝐞𝐱𝐩𝐞𝐫𝐭𝐬 𝐜𝐨𝐧𝐧𝐞𝐜𝐭?🌍

myECTRIMS isn’t just a library—it’s a global hub for the MS community.

Whether you are looking for a mentor, a collaborator, or a new educational opportunity, you can tailor the platform to fit your professional goals.

𝐖𝐢𝐭𝐡 𝐦𝐲𝐄𝐂𝐓𝐑𝐈𝐌𝐒, 𝐲𝐨𝐮 𝐜𝐚𝐧:
🔹 Tailor Your Content Feed: Filter and prioritise research, educational materials, and updates that align with your career and interests.
🔹 Connect with Peers & Experts: Build your network and engage with leading MS researchers and professionals globally.
🔹 Stay Informed: Access the latest scientific insights and resources in your areas of interest.
🔹 Advance Your Career: Find mentors to enhance your professional development.

Log in now to start customising your experience and get the most out of myECTRIMS!

🔗 Make the platform yours today: https://my.ectrims.eu/

10/02/2026

📢 New in Multiple Sclerosis Journal: A scoping review led by Maria Pia Sormani of Università di Genova identifies and synthesises the emerging literature on social determinants of health in people with MS in Italy.

Read more here: https://journals.sagepub.com/toc/msja/current

The study reveals a strong focus on s*x and gender, alongside significant gaps in other key areas.

07/02/2026

🎧 𝐄𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝐩𝐨𝐝𝐜𝐚𝐬𝐭: 𝐧𝐞𝐰𝐥𝐲 𝐩𝐫𝐞𝐬𝐞𝐧𝐭𝐞𝐝 𝐟𝐞𝐧𝐞𝐛𝐫𝐮𝐭𝐢𝐧𝐢𝐛 𝐝𝐚𝐭𝐚 𝐢𝐧 𝐩𝐫𝐢𝐦𝐚𝐫𝐲 𝐩𝐫𝐨𝐠𝐫𝐞𝐬𝐬𝐢𝐯𝐞 𝐌𝐒

Clinical trial results unveiled just moments ago at 2026 suggest fenebrutinib may be a novel and effective treatment option for people living with primary progressive multiple sclerosis.

In this exclusive ECTRIMS Podcast episode providing the first expert discussion of the complete dataset, FENtrepid trial leads Prof. Amit-Bar Or from University of Pennsylvania Perelman School of Medicine and Dr. Stephen Hauser from University of California San Francisco break down what the results showed.

𝐋𝐢𝐬𝐭𝐞𝐧 𝐧𝐨𝐰:

• Spotify: https://bit.ly/3MksuWl

• Apple: https://apple.co/4rAsUXF

• Website: https://bit.ly/4tjq1MN

These results reflect the efforts of a broader group of investigators and co-authors, and we also gratefully recognise their vital contributions: Jiwon Oh, Gavin Giovannoni, Maria Pia Sormani, Martin S. Weber, Sharon S. Stoll, Jacqueline Nicholas, MD, MPH, H.-Christian von Büdingen, Jon Lopez, Louise Roberts, Miriam Triyatni, Qi Qi, John N. Ratchford, Julie Napieralski, Alexandra Goodyear, MD, MS, Ludwig Kappos [NS1.1]

Podcast moderated by Brett Drummond from MStranslate.

06/02/2026

Save the date for ! The 10th Joint ACTRIMS-ECTRIMS Meeting will foster global knowledge exchange and advance the field of and related disorders.

10 Joint Meetings. One Global MS Community.

📅 When: 21-23 October 2026
📍Metro Toronto Convention Center in Toronto, Canada

Registration opens on 24 March, so mark your calendar now and subscribe to our newsletter to stay informed: https://bit.ly/4caEpAD

Learn more about MSToronto2026: https://bit.ly/4kl2VRI

ACTRIMS

03/02/2026

Best of : RIMS Highlight

A study in people with MS, led by Professor Renato Anghinah of Hospital das Clínicas da Faculdade de Medicina da USP shows that vertical gaze performance, measured by eye tracking, correlates with patient-reported visual difficulties assessed via the National Eye Institute Visual Function Questionnaire (NEIVFQ-25). These findings suggest that eye-tracking can help validate and better understand visual difficulties in MS.

📌 Explore this and other top-rated abstracts in the Best of Slide Decks on myECTRIMS: https://my.ectrims.eu/bestofslidedecks

30/01/2026

⏳Final days to revisit !

Catch up on over 100 scientific sessions on demand, available until 31 January 2026.

📽️ Rewatch Scientific Session 3: Ageing and Senescence

Watch the replay here 👉https://ectrims-congress.virtual-meeting.org/programme/session/67890

"Is immunosenescence the chicken or the egg in driving disease progression"? This question, posed by Professor Thomas Berger (Universität Wien), Co-Chair of the session, framed the discussion and guided the session throughout.

30/01/2026

🎥 ECTRIMS 2025: A Lasting Impact for Barcelona’s MS Community

The 2025 ECTRIMS Congress did more than bring scientific innovation to Barcelona – it left a lasting legacy. Key local partners – Fundació Esclerosi Múltiple, Barcelona Convention Bureau, Esclerosis Múltiple España, Consorci de Turisme de Barcelona, Barcelona Convention Bureau, and Barcelona Activa – have launched a project to support people living with MS in their professional lives.

In Catalonia alone, more than 12,000 people live with multiple sclerosis, and many are only able to remain in their jobs for around 10 years after diagnosis. This collaboration has already resulted in an online training course for the local business community that:

- Provides clear information and dispels myths about hashtag
- Offers practical tools to strengthen diversity management
- Promotes more inclusive and competitive workplaces

We are proud to have played a role in helping spark this important initiative.

Through efforts like our annual Patient Community Day, ECTRIMS creates meaningful spaces where people living with MS, patient organisations, clinicians, and researchers come together to share knowledge and address unmet needs.

👉 Explore how Patient Community Day 2025 at Barcelona's CCIB is driving real-world change and long-term legacy in Barcelona in our annual Impact Report: https://www.ectrimspatientcommunity.eu/impact-report/

Adresse

Reinacherstrasse 131
Basel
4053

Telefon

+41616867777

Webseite

http://www.ectrims.eu/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von European Committee for Treatment & Research in Multiple Sclerosis erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.